Behandlingen af BRAF-muteret metastatisk melanom med BRAF/MEK-inhibitorer bedrer prognosen

Translated title of the contribution: Treatment of BRAF-mutated metastatic melanoma

Tessa Bystrup Boyles, Inge Marie Svane, Lars Bastholt, Henrik Schmidt

Abstract

Melanoma is an aggressive form of skin cancer which is the cause of a great number of skin cancer-related deaths worldwide and about 300 deaths in Denmark. After several years of failure of treatment of metastatic melanoma, the development of BRAF- and later MEK inhibitors was considered revolutionary. Treatment with BRAF inhibitors alone and especially in combination with a MEK inhibitor improves outcome for patients with BRAF V600-mutated metastatic melanoma. However, even when treated with the combination of the inhibitors, many patients develop acquired resistance within a year.

Translated title of the contributionTreatment of BRAF-mutated metastatic melanoma
Original languageDanish
Article numberV02160126
JournalUgeskrift for Laeger
Volume178
Number of pages4
ISSN0041-5782
Publication statusPublished - 2016

Keywords

  • English Abstract
  • Journal Article

Fingerprint

Dive into the research topics of 'Treatment of BRAF-mutated metastatic melanoma'. Together they form a unique fingerprint.

Cite this